Biomass
$1.70
+6%
Broad Spectrum Distillate
$3,000.00
+3%
CBD Isolate
$1,100.00
+0%
CBG Isolate
$6,000.00
-7%
Water Soluble CBD Isolate
$2,300.00
+5%
Water Soluble CBD Broad Spectrum
$2,800.00
+2%
Back to news
1. March 2021
CBD Medical News Research

Stero Biotechs Publishes Study of CBD-based Treatment for Covid-19 Severe Patients

Stero Biotechs, an Israel-based, clinical-stage company focused on Cannabidiol (CBD) formulation research and development, has released initial results from a clinical Exploratory Study of CBD-based treatment for COVID-19 severe patients.

Stero Biotechs Publishes Study of CBD-based Treatment for Covid-19 Severe Patients

Image | Pexels.com

In preliminary data CBD has been shown to have a beneficial effect on a number of inflammatory markers that are elevated in Covid-19 patients and may have clinical merits as well.

The clinical trial, covered by Stero’s IP for CBD Treatment of Severe and Critical COVID-19 Pulmonary Infection, is conducted at Rabin Medical Center, the leading hospital of Clalit HMO, in the global efforts of fighting the Covid-19 virus.

In recent years, several clinical studies have been conducted at Beilinson Hospital, such as “Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study” that have demonstrated the moderating effect of one of the components of the cannabis plant, called Cannabidiol, on immune system cells.

A series of studies led by Dr. Moshe Yeshurun, director of the bone marrow transplant unit at the Davidoff Center, showed that CBD significantly reduces inflammatory morbidity called graft-versus-host disease, in patients who have undergone bone marrow transplantation, a syndrome caused by donor immune cells attacking the transplanted patients’ organs.

CBD and COVID-19

Based on the previous studies, Dr. Yeshurun and Dr. Ilya Kagan, Director of the Intensive care Units of COVID-19 patients in Rabin Medical Center, conducted a pilot clinical trial aiming the explore the safety and efficacy of CBD in reducing the raging inflammatory process that harms patients with severe and critical COVID-19 infection.

Data from the study has shown that CBD can have a beneficial effect on a number of inflammatory markers that are elevated in Covid-19 patients. The investigators emphasize that although the relatively low number of patients is insufficient in creating conclusive evidence, the laboratory and clinical results so far, justify the design of a randomized controlled study comparing outcomes of patients with and without CBD.

The ongoing clinical trial commenced early on 2021 after receiving Helsinki Committee approval and has currently recruited 11 patients out of the planned amount of up to for 20 patient. The study aims to benefit Covid-19 patients with severe acute respiratory distress syndrome (ARDS). The treatment cycle is for 14-28 days with a subsequent follow up period of the same length.

Source | Stero Biotechs